Background and aims RNA interference has been extensively explored in patients with chronic hepatitis B (CHB) infection. We aimed to characterise the long-term efficacy of small interfering RNA (siRNA ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
The SCP has its own share of malevolent toys, but SCP-2295 doesn’t have an evil bone in its body. It doesn’t have any bones in fact but this teddy bear’s mission in life is to heal those in need of ...
Vivace Therapeutics Inc. reported preclinical efficacy data of VT-3989, a TEAD inhibitor, in in vitro and in vivo models of aggressive meningioma. VT-3989 is in early clinical development for the ...
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to ...
VT3989, a transcriptional enhanced associate domain autopalmitoylation inhibitor, targets the Hippo pathway in mesothelioma treatment. The FDA's fast track designation aims to expedite VT3989's ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Proteins undergo unfolding and subsequent denaturation by the alternation of physical ...
SAN MATEO, Calif., July 30, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, ...
VT3989 targets TEAD proteins in the Hippo pathway, aiming to inhibit cancer cell growth in mesothelioma. Orphan drug designation offers benefits like tax credits, FDA fee exemptions, and market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results